NCT05794672 is a Phase 1 clinical trial of Elarekibep in Healthy Subjects (Indication: Asthma), sponsored by AstraZeneca.

Who is sponsoring NCT05794672?

NCT05794672 is sponsored by AstraZeneca.

What drugs are being tested in NCT05794672?

Interventions in NCT05794672: Elarekibep, Placebo.

What condition does NCT05794672 study?

NCT05794672 studies Healthy Subjects (Indication: Asthma).

Is NCT05794672 still recruiting?

NCT05794672 is currently terminated. Last updated 18 July 2023.

Last reviewed 2023-07-18 · How we verify

NCT05794672

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects

Terminated Phase 1 Last updated 18 July 2023

What this trial tests

Phase 1 trial testing Elarekibep in Healthy Subjects (Indication: Asthma) in 30 participants. Terminated before completion.

Timeline

11 April 2023

Primary endpoint
8 July 2023

8 July 2023

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	11 April 2023
Primary completion	8 July 2023
Estimated completion	8 July 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Elarekibep — full drug profile →
Placebo

Conditions studied

Healthy Subjects (Indication: Asthma) — all drugs for Healthy Subjects (Indication: Asthma) →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 20 to 55, any sex, with Healthy Subjects (Indication: Asthma). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the safety, tolerability and pharmacokinetics (PK) of elarekibep after single and multiple doses given twice daily (BID) by inhalation or intravenous (IV) in healthy Japanese subjects compared with placebo.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons.
Hussain M, Liu G. · · 2024 · cited 60× · PMID 38474348 · DOI 10.3390/cells13050384

Verify or expand the search:

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05794672 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 18 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05794672.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing